Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) Sees Significant Increase in Short Interest

Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) was the target of a large increase in short interest in the month of August. As of August 31st, there was short interest totaling 15,579 shares, an increase of 1,923.2% from the August 15th total of 770 shares. Based on an average daily volume of 17,581 shares, the short-interest ratio is currently 0.9 days. Currently, 0.9% of the shares of the company are short sold.

Hedge Funds Weigh In On Bolt Biotherapeutics

A number of institutional investors have recently bought and sold shares of BOLT. Nan Fung Group Holdings Ltd bought a new stake in Bolt Biotherapeutics during the second quarter valued at about $19,250. Squarepoint Ops LLC raised its stake in shares of Bolt Biotherapeutics by 19.8% in the third quarter. Squarepoint Ops LLC now owns 14,836 shares of the company’s stock worth $79,000 after buying an additional 2,448 shares during the period. Shay Capital LLC purchased a new position in shares of Bolt Biotherapeutics during the 3rd quarter valued at about $85,000. Susquehanna International Group LLP purchased a new position in shares of Bolt Biotherapeutics during the 3rd quarter valued at about $89,000. Finally, Nano Cap New Millennium Growth Fund L P bought a new position in shares of Bolt Biotherapeutics during the 4th quarter valued at approximately $112,000. 86.70% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on BOLT shares. HC Wainwright reissued a “buy” rating and set a $7.00 price target on shares of Bolt Biotherapeutics in a report on Thursday, May 28th. Rodman & Renshaw began coverage on Bolt Biotherapeutics in a report on Thursday, May 28th. They issued a “buy” rating and a $22.00 price objective for the company. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Bolt Biotherapeutics in a research report on Friday, July 17th. Two analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Bolt Biotherapeutics presently has an average rating of “Hold” and a consensus price target of $14.50.

Bolt Biotherapeutics Stock Performance

Shares of BOLT traded up $0.22 on Friday, reaching $3.95. The company’s stock had a trading volume of 77,077 shares, compared to its average volume of 18,826. The stock’s 50 day simple moving average is $3.86 and its two-hundred day simple moving average is $4.33. The company has a debt-to-equity ratio of 1.47, a current ratio of 2.61 and a quick ratio of 2.61. The stock has a market capitalization of $7.62 million, a P/E ratio of -0.24 and a beta of 1.09. Bolt Biotherapeutics has a 12-month low of $3.13 and a 12-month high of $7.20.

Bolt Biotherapeutics (NASDAQ:BOLT) last announced its earnings results on Tuesday, August 11th. The company reported ($4.57) EPS for the quarter, missing analysts’ consensus estimates of ($3.39) by ($1.18). The business had revenue of $0.01 million for the quarter, compared to analysts’ expectations of $0.50 million. Bolt Biotherapeutics had a negative net margin of 611.47% and a negative return on equity of 126.23%. Research analysts forecast that Bolt Biotherapeutics will post -11.1 earnings per share for the current fiscal year.

About Bolt Biotherapeutics

Bolt Biotherapeutics is a clinical-stage immuno-oncology company focused on developing novel targeted therapies that engage both innate and adaptive immune responses against cancer. The company’s proprietary Biologics-Driven Checkpoint (BDC) platform combines tumor-targeting antibodies with innate immune agonists to activate antigen-presenting cells within the tumor microenvironment, thereby promoting robust T-cell mediated tumor cell killing. Its lead candidate, BDC-1001, couples a HER2-directed monoclonal antibody with a Toll-like receptor 7/8 agonist and is currently in Phase I clinical trials for HER2-positive solid tumors.